Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of ATP production

Jean Francois H. Geschwind, Young H. Ko, Michael S. Torbenson, Carolyn Magee, Peter L. Pedersen

Research output: Contribution to journalArticlepeer-review

237 Scopus citations

Abstract

Most types of cancer are difficult to eradicate and some, like liver carcinomas, are almost always fatal. Significantly, we report here that direct intraarterial delivery of 3-bromopyruvate (3-BrPA), a potent inhibitor of cell ATP production, to liver-implanted rabbit tumors, inflicts a rapid, lethal blow to most cancer cells therein. Moreover, systemic delivery of 3-BrPA suppresses "metastatic" tumors that arise in the lungs. In both cases, there is no apparent harm to other organs or to the animals. Thus, intraarterial delivery of agents like 3-BrPA directly to the site of the primary tumor, followed by systemic delivery only when necessary, may represent a powerful new strategy for arresting the growth of liver and other cancers while minimizing toxic side effects.

Original languageEnglish (US)
Pages (from-to)3909-3913
Number of pages5
JournalCancer research
Volume62
Issue number14
StatePublished - Jul 15 2002

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Novel therapy for liver cancer: Direct intraarterial injection of a potent inhibitor of ATP production'. Together they form a unique fingerprint.

Cite this